Topoisomerase II inhibitors induce DNA damage-dependent interferon responses circumventing ebola virus immune evasion

mBio

Volumn 8, Issue 2, 2017, Pages

  Luthra, Priya ^a   Aguirre, Sebastian ^b   Yen, Benjamin C ^b   Pietzsch, Colette A ^c   Sanchez Aparicio, Maria T ^b   Tigabu, Bersabeh ^c   Morlock, Lorraine K ^d   García Sastre, Adolfo ^b   Leung, Daisy W ^e   Williams, Noelle S ^d   Fernandez Sesma, Ana ^b   Bukreyev, Alexander ^c,f   Basler, Christopher F ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

ATM signaling; C GAS STING pathway; DNA damage; Ebola virus; Innate immune responses

Indexed keywords

AKLAVINE; AMINOACRIDINE; ANTHRACYCLINE ANTIBIOTIC AGENT; ATM PROTEIN; CYCLIC GMP ADENOSINE PHOSPHATE SYNTHASE; DAUNORUBICIN; DNA; DOXORUBICIN; EPIRUBICIN; GYRASE INHIBITOR; MEMBRANE PROTEIN; PROTEIN VP35; STIMULATOR OF INTERFERON GENE PROTEIN; SYNTHETASE; UNCLASSIFIED DRUG; VIRAL PROTEIN; ANTIVIRUS AGENT; INTERFERON;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RESPONSE; DNA DAMAGE RESPONSE; EBOLAVIRUS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNE EVASION; IN VITRO STUDY; INTERFERON INDUCTION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION; CELL LINE; DNA DAMAGE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANTIVIRAL AGENTS; CELL LINE; DNA DAMAGE; EBOLAVIRUS; HUMANS; IMMUNE EVASION; INTERFERONS; TOPOISOMERASE II INHIBITORS; VIRUS REPLICATION;

EID: 85019113636     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00368-17     Document Type: Article

References (89)

1. Mahanty S, Bray M. 2004. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4:487-498. https://doi.org/10.1016/S1473-3099 (04)01103-X.
2. Wong G, Qiu X, Olinger GG, Kobinger GP. 2014. Post-exposure therapy of filovirus infections. Trends Microbiol 22:456-463. https://doi.org/10.1016/j.tim.2014.04.002.
3. Mateo M, Reid SP, Leung LW, Basler CF, Volchkov VE. 2010. Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J Virol 84:1169-1175. https://doi.org/10.1128/JVI.01372-09.
4. Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, Volchkov VE, Nichol ST, Basler CF. 2006. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 80:5156-5167. https://doi.org/10.1128/JVI.02349-05.
5. Reid SP, Valmas C, Martinez O, Sanchez FM, Basler CF. 2007. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol 81:13469-13477. https://doi.org/10.1128/JVI.01097-07.
6. Xu W, Edwards MR, Borek DM, Feagins AR, Mittal A, Alinger JB, Berry KN, Yen B, Hamilton J, Brett TJ, Pappu RV, Leung DW, Basler CF, Amarasinghe GK. 2014. Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe 16:187-200. https://doi.org/10.1016/j.chom.2014.07.008.
7. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. 2009. Tetherinmediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A 106:2886-2891. https://doi.org/10.1073/pnas.0811014106.
8. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Mühlberger E, Bray M, Klenk HD, Palese P, García-Sastre A. 2003. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 77: 7945-7956. https://doi.org/10.1128/JVI.77.14.7945-7956.2003.
9. Basler CF, Wang X, Mühlberger E, Volchkov V, Paragas J, Klenk HD, García-Sastre A, Palese P. 2000. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A 97:12289-12294. https://doi.org/10.1073/pnas.220398297.
10. Hartman AL, Towner JS, Nichol STA. 2004. A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology 328:177-184. https://doi.org/10.1016/j.virol.2004.07.006.
11. Leung DW, Prins KC, Borek DM, Farahbakhsh M, Tufariello JM, Ramanan P, Nix JC, Helgeson LA, Otwinowski Z, Honzatko RB, Basler CF, Amarasinghe GK. 2010. Structural basis for ds RNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol 17:165-172. https://doi.org/10.1038/nsmb.1765.
12. Prins KC, Delpeut S, Leung DW, Reynard O, Volchkova VA, Reid SP, Ramanan P, Cárdenas WB, Amarasinghe GK, Volchkov VE, Basler CF. 2010. Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J Virol 84:3004-3015. https://doi.org/10.1128/JVI.02459-09.
13. Schümann M, Gantke T, Mühlberger E. 2009. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J Virol 83:8993-8997. https://doi.org/10.1128/JVI.00523-09.
14. Cárdenas WB, Loo YM, Gale M, Hartman AL, Kimberlin CR, Martínez-Sobrido L, Saphire EO, Basler CF. 2006. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol 80:5168-5178. https://doi.org/10.1128/JVI.02199-05.
15. Yen B, Mulder LC, Martinez O, Basler CF. 2014. Molecular basis for ebolavirus VP35 suppression of human dendritic cell maturation. J Virol 88:12500-12510. https://doi.org/10.1128/JVI.02163-14.
16. Lubaki NM, Ilinykh P, Pietzsch C, Tigabu B, Freiberg AN, Koup RA, Bukreyev A. 2013. The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. J Virol 87:7471-7485. https://doi.org/10.1128/JVI.03316-12.
17. Hartman AL, Bird BH, Towner JS, Antoniadou ZA, Zaki SR, Nichol ST. 2008. Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of Ebola virus. J Virol 82:2699-2704. https://doi.org/10.1128/JVI.02344-07.
18. Hartman AL, Dover JE, Towner JS, Nichol ST. 2006. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J Virol 80:6430-6440. https://doi.org/10.1128/JVI.00044-06.
19. Chan YK, Gack MU. 2016. Viral evasion of intracellular DNA and RNA sensing. Nat Rev Microbiol 14:360-373. https://doi.org/10.1038/nrmicro.2016.45.
20. Kell AM, Gale M, Jr. 2015. RIG-I in RNA virus recognition. Virology 479-480:110-121. https://doi.org/10.1016/j.virol.2015.02.017.
21. Brzostek-Racine S, Gordon C, Van Scoy S, Reich NC. 2011. The DNA damage response induces IFN. J Immunol 187:5336-5345. https://doi.org/10.4049/jimmunol.1100040.
22. Härtlova A, Erttmann SF, Raffi FA, Schmalz AM, Resch U, Anugula S, Lienenklaus S, Nilsson LM, Kröger A, Nilsson JA, Ek T, Weiss S, Gekara NO. 2015. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity 42:332-343. https://doi.org/10.1016/j.immuni.2015.01.012.
23. Hussner J, Ameling S, Hammer E, Herzog S, Steil L, Schwebe M, Niessen J, Schroeder HW, Kroemer HK, Ritter CA, Völker U, Bien S. 2012. Regulation of interferon-inducible proteins by doxorubicin via interferon gamma-Janus tyrosine kinase-signal transducer and activator of transcription signaling in tumor cells. Mol Pharmacol 81:679-688. https://doi.org/10.1124/mol.111.075994.
24. Kurz EU, Douglas P, Lees-Miller SP. 2004. Doxorubicin activates ATMdependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem 279: 53272-53281. https://doi.org/10.1074/jbc.M406879200.
25. Kurz EU, Lees-Miller SP. 2004. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst) 3:889-900. https://doi.org/10.1016/j.dnarep.2004.03.029.
26. Li N, Banin S, Ouyang H, Li GC, Courtois G, Shiloh Y, Karin M, Rotman G. 2001. ATM is required for Ikappa B kinase (IKKk) activation in response to DNA double strand breaks. J Biol Chem 276:8898-8903. https://doi.org/10.1074/jbc.M009809200.
27. Sun L, Wu J, Du F, Chen X, Chen ZJ. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339:786-791. https://doi.org/10.1126/science.1232458.
28. Wu J, Sun L, Chen X, Du F, Shi H, Chen C, Chen ZJ. 2013. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339:826-830. https://doi.org/10.1126/science.1229963.
29. Diner EJ, Burdette DL, Wilson SC, Monroe KM, Kellenberger CA, Hyodo M, Hayakawa Y, Hammond MC, Vance RE. 2013. The innate immune DNA sensor c GAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep 3:1355-1361. https://doi.org/10.1016/j.celrep.2013.05.009.
30. Ishikawa H, Barber GN. 2008. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455:674-678. https://doi.org/10.1038/nature07317.
31. Ishikawa H, Ma Z, Barber GN. 2009. STING regulates intracellular DNAmediated, type I interferon-dependent innate immunity. Nature 461: 788-792. https://doi.org/10.1038/nature08476.
32. Liu H, Wang H, Xiang D, Guo W. 2016. Pharmaceutical measures to prevent doxorubicin-induced cardiotoxicity. Mini Rev Med Chem 17: 44-50. https://doi.org/10.2174/1389557516666160621083659.
33. Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC, Kirschenbaum S, Silber R, Potmesil M. 1989. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res 49:5969-5978.
34. Burgess DJ, Doles J, Zender L, Xue W, Ma B, Mc Combie WR, Hannon GJ, Lowe SW, Hemann MT. 2008. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A 105: 9053-9058. https://doi.org/10.1073/pnas.0803513105.
35. Bracci L, Schiavoni G, Sistigu A, Belardelli F. 2014. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21:15-25. https://doi.org/10.1038/cdd.2013.67.
36. Hannesdóttir L, Tymoszuk P, Parajuli N, Wasmer MH, Philipp S, Daschil N, Datta S, Koller JB, Tripp CH, Stoitzner P, Müller-Holzner E, Wiegers GJ, Sexl V, Villunger A, Doppler W. 2013. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol 43: 2718-2729. https://doi.org/10.1002/eji.201242505.
37. Fortune JM, Osheroff N. 2000. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64:221-253. https://doi.org/10.1016/S0079-6603(00)64006-0.
38. Kim T, Kim TY, Song YH, Min IM, Yim J, Kim TK. 1999. Activation of interferon regulatory factor 3 in response to DNA-damaging agents. J Biol Chem 274:30686-30689. https://doi.org/10.1074/jbc.274.43.30686.
39. Wheeler HR, Geczy CL. 1990. Induction of macrophage procoagulant expression by cisplatin, daunorubicin and doxorubicin. Int J Cancer 46:626-632. https://doi.org/10.1002/ijc.2910460413.
40. Zhang JH, Chung TD, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73. https://doi.org/10.1177/1087057 19900400206.
41. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I. 2010. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375:1896-1905. https://doi.org/10.1016/S0140-6736(10)60357-1.
42. Aubel-Sadron G, Londos-Gagliardi D. 1984. Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie 66:333-352. https://doi.org/10.1016/0300-9084(84)90018-X.
43. Strelitz F, Flon H, Weiss U, Asheshov IN. 1956. Aklavin, an antibiotic substance with antiphage activity. J Bacteriol 72:90-94.
44. René B, Fossé P, Khélifa T, Jacquemin-Sablon A, Bailly C. 1997. Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1= substitute on the aniline nucleus. Bull Cancer 84:941-948. (In French.)
45. Vock EH, Lutz WK, Hormes P, Hoffmann HD, Vamvakas S. 1998. Discrimination between genotoxicity and cytotoxicity in the induction of DNA double-strand breaks in cells treated with etoposide, melphalan, cisplatin, potassium cyanide, Triton X-100, and gamma-irradiation. Mutat Res 413:83-94. https://doi.org/10.1016/S1383-5718(98)00019-9.
46. Lavin MF. 2008. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 9:759-769. https://doi.org/10.1038/nrm2514.
47. Lavin MF, Shiloh Y. 1997. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol 15:177-202. https://doi.org/10.1146/annurev.immunol.15.1.177.
48. Shiloh Y. 2006. The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci 31:402-410. https://doi.org/10.1016/j.tibs.2006.05.004.
49. Pamment J, Ramsay E, Kelleher M, Dornan D, Ball KL. 2002. Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway. Oncogene 21:7776-7785. https://doi.org/10.1038/sj.onc.1205981.
50. Ferguson BJ, Mansur DS, Peters NE, Ren H, Smith GL. 2012. DNA-PK is a DNA sensor for IRF-3-dependent innate immunity. Elife 1:e00047. https://doi.org/10.7554/e Life.00047.
51. Zhang X, Brann TW, Zhou M, Yang J, Oguariri RM, Lidie KB, Imamichi H, Huang DW, Lempicki RA, Baseler MW, Veenstra TD, Young HA, Lane HC, Imamichi T. 2011. Cutting edge: Ku70 is a novel cytosolic DNA sensor that induces type III rather than type I IFN. J Immunol 186:4541-4545. https://doi.org/10.4049/jimmunol.1003389.
52. Gasser S, Raulet DH. 2006. The DNA damage response arouses the immune system. Cancer Res 66:3959-3962. https://doi.org/10.1158/0008-5472.CAN-05-4603.
53. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GC. 2004. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64:9152-9159. https://doi.org/10.1158/0008-5472.CAN-04-2727.
54. Dupré A, Boyer-Chatenet L, Sattler RM, Modi AP, Lee JH, Nicolette ML, Kopelovich L, Jasin M, Baer R, Paull TT, Gautier J. 2008. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol 4:119-125. https://doi.org/10.1038/nchembio.63.
55. Gudkov AV, Zelnick CR, Kazarov AR, Thimmapaya R, Suttle DP, Beck WT, Roninson IB. 1993. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II c DNA. Proc Natl Acad Sci U S A 90:3231-3235. https://doi.org/10.1073/pnas.90.8.3231.
56. Ishii KJ, Coban C, Kato H, Takahashi K, Torii Y, Takeshita F, Ludwig H, Sutter G, Suzuki K, Hemmi H, Sato S, Yamamoto M, Uematsu S, Kawai T, Takeuchi O, Akira S. 2006. A toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 7:40-48. https://doi.org/10.1038/ni1282.
57. Stetson DB, Medzhitov R. 2006. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 24:93-103. https://doi.org/10.1016/j.immuni.2005.12.003.
58. Ablasser A, Hornung V. 2013. DNA sensing unchained. Cell Res 23: 585-587. https://doi.org/10.1038/cr.2013.28.
59. Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Röhl I, Hopfner KP, Ludwig J, Hornung V. 2013. c GAS produces a 2=-5=-linked cyclic dinucleotide second messenger that activates STING. Nature 498:380-384. https://doi.org/10.1038/nature12306.
60. Abe T, Barber GN. 2014. Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-κB activation through TBK1. J Virol 88:5328-5341. https://doi.org/10.1128/JVI.00037-14.
61. Zhang X, Shi H, Wu J, Zhang X, Sun L, Chen C, Chen ZJ. 2013. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell 51:226-235. https://doi.org/10.1016/j.molcel.2013.05.022.
62. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, Hayakawa Y, Vance RE. 2011. STING is a direct innate immune sensor of cyclic di-GMP. Nature 478:515-518. https://doi.org/10.1038/nature10429.
63. Diner EJ, Vance RE. 2014. Taking the STING out of cytosolic DNA sensing. Trends Immunol 35:1-2. https://doi.org/10.1016/j.it.2013.10.011.
64. Civril F, Deimling T, de Oliveira Mann CC, Ablasser A, Moldt M, Witte G, Hornung V, Hopfner KP. 2013. Structural mechanism of cytosolic DNA sensing by c GAS. Nature 498:332-337. https://doi.org/10.1038/nature12305.
65. Kranzusch PJ, Lee AS, Berger JM, Doudna JA. 2013. Structure of human c GAS reveals a conserved family of second-messenger enzymes in innate immunity. Cell Rep 3:1362-1368. https://doi.org/10.1016/j.celrep.2013.05.008.
66. Kranzusch PJ, Vance RE. 2013. c GAS dimerization entangles DNA recognition. Immunity 39:992-994. https://doi.org/10.1016/j.immuni.2013.11.012.
67. Deng X, Ljunggren-Rose A, Maas K, Sriram S. 2005. Defective ATM-p53-mediated apoptotic pathway in multiple sclerosis. Ann Neurol 58: 577-584. https://doi.org/10.1002/ana.20600.
68. Westbrook AM, Schiestl RH. 2010. Atm-deficient mice exhibit increased sensitivity to dextran sulfate sodium-induced colitis characterized by elevated DNA damage and persistent immune activation. Cancer Res 70:1875-1884. https://doi.org/10.1158/0008-5472.CAN-09-2584.
69. Mc Cabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O’Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. 2006. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66:8109-8115. https://doi.org/10.1158/0008-5472.CAN-06-0140.
70. Lahaye X, Manel N. 2014. HIV-2 reveals an antiviral mechanism of detection by innate immunity. Med Sci (Paris) 30:610-613. https://doi.org/10.1051/medsci/20143006004.
71. Yang YG, Lindahl T, Barnes DE. 2007. Trex1 exonuclease degrades ss DNA to prevent chronic checkpoint activation and autoimmune disease. Cell 131:873-886. https://doi.org/10.1016/j.cell.2007.10.017.
72. Gall A, Treuting P, Elkon KB, Loo YM, Gale M, Barber GN, Stetson DB. 2012. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 36:120-131. https://doi.org/10.1016/j.immuni.2011.11.018.
73. Fye JM, Orebaugh CD, Coffin SR, Hollis T, Perrino FW. 2011. Dominant mutation of the TREX1 exonuclease gene in lupus and Aicardi-Goutieres syndrome. J Biol Chem 286:32373-32382. https://doi.org/10.1074/jbc.M111.276287.
74. Grieves JL, Fye JM, Harvey S, Grayson JM, Hollis T, Perrino FW. 2015. Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease. Proc Natl Acad Sci U S A 112: 5117-5122. https://doi.org/10.1073/pnas.1423804112.
75. Bale S, Julien JP, Bornholdt ZA, Krois AS, Wilson IA, Saphire EO. 2013. Ebolavirus VP35 coats the backbone of double-stranded RNA for interferon antagonism. J Virol 87:10385-10388. https://doi.org/10.1128/JVI.01452-13.
76. Leung DW, Ginder ND, Fulton DB, Nix J, Basler CF, Honzatko RB, Amarasinghe GK. 2009. Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci U S A 106:411-416. https://doi.org/10.1073/pnas.0807854106.
77. Luthra P, Ramanan P, Mire CE, Weisend C, Tsuda Y, Yen B, Liu G, Leung DW, Geisbert TW, Ebihara H, Amarasinghe GK, Basler CF. 2013. Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe 14:74-84. https://doi.org/10.1016/j.chom.2013.06.010.
78. Chang TH, Kubota T, Matsuoka M, Jones S, Bradfute SB, Bray M, Ozato K. 2009. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLo S Pathog 5:e1000493. https://doi.org/10.1371/journal.ppat.1000493.
79. Prins KC, Cárdenas WB, Basler CF. 2009. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol 83:3069-3077. https://doi.org/10.1128/JVI.01875-08.
80. Crow YJ, Rehwinkel J. 2009. Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Hum Mol Genet 18:R130-R136. https://doi.org/10.1093/hmg/ddp293.
81. Spiropoulou CF, Ranjan P, Pearce MB, Sealy TK, Albariño CG, Gangappa S, Fujita T, Rollin PE, Nichol ST, Ksiazek TG, Sambhara S. 2009. RIG-I activation inhibits ebolavirus replication. Virology 392:11-15. https://doi.org/10.1016/j.virol.2009.06.032.
82. Hartman AL, Ling L, Nichol ST, Hibberd ML. 2008. Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J Virol 82:5348-5358. https://doi.org/10.1128/JVI.00215-08.
83. Bray M. 2005. Pathogenesis of viral hemorrhagic fever. Curr Opin Immunol 17:399-403. https://doi.org/10.1016/j.coi.2005.05.001.
84. Bray M, Geisbert TW. 2005. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 37:1560-1566. https://doi.org/10.1016/j.biocel.2005.02.018.
85. Cai X, Chiu YH, Chen ZJ. 2014. The c GAS-c GAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell 54:289-296. https://doi.org/10.1016/j.molcel.2014.03.040.
86. Li XD, Wu J, Gao D, Wang H, Sun L, Chen ZJ. 2013. Pivotal roles of c GAS-c GAMP signaling in antiviral defense and immune adjuvant effects. Science 341:1390-1394. https://doi.org/10.1126/science.1244040.
87. Pichlmair A, Kandasamy K, Alvisi G, Mulhern O, Sacco R, Habjan M, Binder M, Stefanovic A, Eberle CA, Goncalves A, Bürckstümmer T, Müller AC, Fauster A, Holze C, Lindsten K, Goodbourn S, Kochs G, Weber F, Bartenschlager R, Bowie AG, Bennett KL, Colinge J, Superti-Furga G. 2012. Viral immune modulators perturb the human molecular network by common and unique strategies. Nature 487:486-490. https://doi.org/10.1038/nature11289.
88. Tanaka Y, Chen ZJ. 2012. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal 5:ra20. https://doi.org/10.1126/scisignal.2002521.
89. Nakhaei P, Hiscott J, Lin R. 2010. STING-ing the antiviral pathway. J Mol Cell Biol 2:110-112. https://doi.org/10.1093/jmcb/mjp048